Validation of low-volume sampling devices for pharmacokinetic analysis: technical and logistical challenges and solutions

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ. At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials. Oncologist 23(10), 1242–1249 (2018).
  MedlineGoogle Scholar
• 2. Guerra Valero Y, Dorofaeff T, Parker L et al. Microsampling to support pharmacokinetic clinical studies in pediatrics. Pediatr. Res. 91(6), 1557–1561 (2022).
  MedlineGoogle Scholar
• 3. Guerra Valero YC, Roberts JA, Lipman J et al. Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: a bridging study. J. Pharm. Biomed. Anal. 169, 288–292 (2019).
  MedlineGoogle Scholar
• 4. Kothare PA, Bateman KP, Dockendorf M et al. An integrated strategy for implementation of dried blood spots in clinical development programs. AAPS J. 18(2), 519–527 (2016). •• Case study of how to implement dried blood spots from assay development, validation, clinical trial application and regulatory perspective.
  Medline CASGoogle Scholar
• 5. Li CC, Dockendorf M, Kowalski K et al. Population PK analyses of ubrogepant (MK-1602), a CGRP receptor antagonist: enriching in-clinic plasma PK sampling with outpatient dried blood spot sampling. J. Clin. Pharmacol. 58(3), 294–303 (2018).
  Medline CASGoogle Scholar
• 6. Verhaeghe T, Meulder M, Hillewaert V, Dillen L, Stieltjes H. Capillary microsampling in clinical studies: opportunities and challenges in two case studies. Bioanalysis 12(13), 905–918 (2020).
  CASGoogle Scholar
• 7. Dubois J, Karuppan S, Savuto P. Increased enrollment efficiency with point-of-care pre-screening. Appl. Clin. Trials. 26(8), 34–37 (2017).
  Google Scholar
• 8. De Jesus VR, Chace DH. Commentary on the history and quantitative nature of filter paper used in blood collection devices. Bioanalysis 4(6), 645–647 (2012).
  Google Scholar
• 9. Kennedy RM, Luhmann J, Zempsky WT. Clinical implications of unmanaged needle-insertion pain and distress in children. Pediatrics 122(Suppl. 3), S130–S133 (2008).
  MedlineGoogle Scholar
• 10. Kern SE. Challenges in conducting clinical trials in children: approaches for improving performance. Expert Rev. Clin. Pharmacol. 2(6), 609–617 (2009).
  MedlineGoogle Scholar
• 11. Martial LC, Aarnoutse RE, Schreuder MF et al. Cost evaluation of dried blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children. PLOS ONE 11(12), e0167433 (2016).
  MedlineGoogle Scholar
• 12. Spooner N, Anderson KD, Siple J et al. Microsampling: considerations for its use in pharmaceutical drug discovery and development. Bioanalysis 11(10), 1015–1038 (2019).
  CASGoogle Scholar
• 13. Hall EM, Flores SR, De Jesus VR. Influence of Hematocrit and total-spot volume on performance characteristics of dried blood spots for newborn screening. Int. J. Neonatal Screen. 1(2), 69–78 (2015). • Detailed description of current strategies for coping with the hematocrit problem in dried blood spot (DBS) analysis.
  MedlineGoogle Scholar
• 14. Koster RA, Alffenaar JW, Greijdanus B, Uges DR. Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta 115, 47–54 (2013).
  Medline CASGoogle Scholar
• 15. Kip AE, Kiers KC, Rosing H et al. Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples. J. Pharm. Biomed. Anal. 135, 160–166 (2017).
  Medline CASGoogle Scholar
• 16. Kopp M, Rychlik M. Assessing volumetric absorptive microsampling coupled with stable isotope dilution assay and liquid chromatography-tandem mass spectrometry as potential diagnostic tool for whole blood 5-methyltetrahydrofolic acid. Front. Nutr. 4, 9 (2017).
  MedlineGoogle Scholar
• 17. Xie I, Xu Y, Anderson M et al. Extractability-mediated stability bias and hematocrit impact: high extraction recovery is critical to feasibility of volumetric adsorptive microsampling (VAMS) in regulated bioanalysis. J. Pharm. Biomed. Anal. 156, 58–66 (2018).
  Medline CASGoogle Scholar
• 18. Delahaye L, Veenhof H, Koch BCP et al. Alternative sampling devices to collect dried blood microsamples: state-of-the-art. Ther. Drug Monit. 43(3), 310–321 (2021).
  MedlineGoogle Scholar
• 19. Leino AD, Takyi-Williams J, Wen B, Sun D, Pai MP. Application of a new volumetric microsampling device for quantitative bioanalysis of immunosuppression. Bioanalysis 14(17), 1141–1152 (2022).
  CASGoogle Scholar
• 20. De Kesel PM, Lambert WE, Stove CP. Does volumetric absorptive microsampling eliminate the hematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study. Anal. Chim Acta. 881, 65–73 (2015). • Evaluated the validity and robustness of volumetric absorptive microsampling (VAMS), and concluded VAMS effectively assists in eliminating the effect of hematocrit.
  MedlineGoogle Scholar
• 21. Mano Y, Kita K, Kusano K. Hematocrit-independent recovery is a key for bioanalysis using volumetric absorptive microsampling devices, Mitra. Bioanalysis 7(15), 1821–1829 (2015).
  CASGoogle Scholar
• 22. Ye Z, Gao H. Evaluation of sample extraction methods for minimizing hematocrit effect on whole blood analysis with volumetric absorptive microsampling. Bioanalysis 9(4), 349–357 (2017).
  CASGoogle Scholar
• 23. Youhnovski N, Bergeron A, Furtado M, Garofolo F. Pre-cut dried blood spot (PCDBS): an alternative to dried blood spot (DBS) technique to overcome hematocrit impact. Rapid Commun. Mass Spectrom. 25(19), 2951–2958 (2011).
  Medline CASGoogle Scholar
• 24. Moorthy GS, Vedar C, Downes KJ et al. Microsampling assays for pharmacokinetic analysis and therapeutic drug monitoring of antimicrobial drugs in children: a critical review. Ther. Drug Monit. 43(3), 335–345 (2021).
  Medline CASGoogle Scholar
• 25. Berm EJ, Odigie B, Bijlsma MJ et al. A clinical validation study for application of DBS in therapeutic drug monitoring of antidepressants. Bioanalysis 8(5), 413–424 (2016).
  CASGoogle Scholar
• 26. Hoogtanders K, van der Heijden J, Christiaans M et al. Therapeutic drug monitoring of tacrolimus with the dried blood spot method. J. Pharm. Biomed. Anal. 44(3), 658–664 (2007).
  Medline CASGoogle Scholar
• 27. Tanna S, Lawson G. Self-sampling and quantitative analysis of DBS: can it shift the balance in over-burdened healthcare systems? Bioanalysis 7(16), 1963–1966 (2015).
  CASGoogle Scholar
• 28. van der Heijden J, de Beer Y, Hoogtanders K et al. Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 50(4), 664–670 (2009).
  MedlineGoogle Scholar
• 29. Patel SR, Bryan P, Spooner N, Timmerman P, Wickremsinhe E. Microsampling for quantitative bioanalysis, an industry update: output from an AAPS/EBF survey. Bioanalysis 11(7), 619–628 (2019). •• Survey conducted across multiple organizations of development and application of different microsampling technologies for drug development, provides a snapshot of current practices and challenges.
  CASGoogle Scholar
• 30. Adolfsson O, Pihlgren M, Toni N et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J. Neurosci. 32(28), 9677–9689 (2012).
  Medline CASGoogle Scholar
• 31. Guthrie H, Honig LS, Lin H et al. Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer's disease treated with escalating doses for up to 133 weeks. J. Alzheimers Dis. 76(3), 967–979 (2020).
  Medline CASGoogle Scholar
• 32. Fiorino G, Gilardi D, Danese S. The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. Ther. Adv. Gastroenterol. 9(4), 503–512 (2016).
  Medline CASGoogle Scholar
• 33. Sandborn WJ, Vermeire S, Tyrrell H et al. Etrolizumab for the treatment of ulcerative colitis and Crohn's disease: an overview of the phase 3 clinical program. Adv. Ther. 37(7), 3417–3431 (2020).
  Medline CASGoogle Scholar
• 34. Salloway S, Honigberg LA, Cho W et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Alzheimers Res Ther. 10(1), 96 (2018).
  MedlineGoogle Scholar
• 35. Rutgeerts PJ, Fedorak RN, Hommes DW et al. A randomised phase 1 study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 62(8), 1122–1130 (2013).
  Medline CASGoogle Scholar
• 36. de Vries R, Barfield M, van de Merbel N et al. The effect of hematocrit on bioanalysis of DBS: results from the EBF DBS-microsampling consortium. Bioanalysis 5(17), 2147–2160 (2013).
  CASGoogle Scholar
• 37. Miao Z, Farnham JG, Hanson G, Podoll T, Reid MJ. Bioanalysis of emixustat (ACU-4429) in whole blood collected with volumetric absorptive microsampling by LC-MS/MS. Bioanalysis 7(16), 2071–2083 (2015).
  CASGoogle Scholar
• 38. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24(1), 49–65 (2010). • Review showing the formula of using hematocrit to correlate analyte concentration between plasma or serum and DBS.
  MedlineGoogle Scholar
• 39. Williams KJ, Lutman J, McCaughey C, Fischer SK. Assessment of low volume sampling technologies: utility in nonclinical and clinical studies. Bioanalysis 13(9), 679–691 (2021).
  CASGoogle Scholar
• 40. Abu-Rabie P, Denniff P, Spooner N, Chowdhry BZ, Pullen FS. Investigation of different approaches to incorporating internal standard in DBS quantitative bioanalytical workflows and their effect on nullifying hematocrit-based assay bias. Anal. Chem. 87(9), 4996–5003 (2015).
  Medline CASGoogle Scholar
• 41. Ackermans MT, de Kleijne V, Martens F, Heijboer AC. Hematocrit and standardization in DBS analysis: a practical approach for hormones mainly present in the plasma fraction. Clin. Chim. Acta 520, 179–185 (2021).
  Medline CASGoogle Scholar
• 42. Undre N, Dawson I, Aluvihare V et al. Validation of a capillary dry blood sample MITRA-based assay for the quantitative determination of systemic tacrolimus concentrations in transplant recipients. Ther. Drug Monit. 43(3), 358–363 (2021).
  Medline CASGoogle Scholar
• 43. Undre N, Hussain I, Meijer J et al. Quantitation of tacrolimus in human whole blood samples using the MITRA microsampling device. Ther. Drug Monit. 43(3), 364–370 (2021).
  Medline CASGoogle Scholar
• 44. Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin. Pharmacokinet. 53(11), 961–973 (2014).
  Medline CASGoogle Scholar
• 45. Li CC, Dockendorf M, Kowalski K et al. Population PK Analyses of ubrogepant (MK-1602), a CGRP receptor antagonist: enriching in-clinic plasma PK sampling with outpatient dried blood spot sampling. J. Clin. Pharmacol. 58(3), 294–303 (2018).
  Medline CASGoogle Scholar
• 46. Kothare PA, Bateman KP, Dockendorf M et al. An integrated strategy for implementation of dried blood spots in clinical development programs. AAPS J. 18(2), 519–527 (2016).
  Medline CASGoogle Scholar
• 47. Evans C, Arnold M, Bryan P et al. Implementing dried blood spot sampling for clinical pharmacokinetic determinations: considerations from the IQ Consortium Microsampling Working Group. AAPS J. 17(2), 292–300 (2015).
  MedlineGoogle Scholar
• 48. Maass KF, Barfield MD, Ito M et al. Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: promise to reality. Clin. Transl. Sci. 15(12), 2785–2795 (2022).
  Medline CASGoogle Scholar
• 49. Wickremsinhe ER, Ji QC, Gleason CR et al. Land O'Lakes workshop on microsampling: enabling broader adoption. AAPS J. 22(6), 135 (2020). •• Perspective from the microsampling workshop providing clarity and recommendations and enabling the broader adoption of microsampling supporting patient-centric drug development.
  MedlineGoogle Scholar